Tech Company Financing Transactions

Entrada Therapeutics Funding Round

Entrada Therapeutics closed a $59 million Series A financing round on 12/19/2018. Investors included 5AM Ventures, MPM Capital and Agent Capital.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

6 Tide St.
Boston, MA 02210
USA

Phone

Undisclosed

Website

www.entradatx.com

Email Address

[email protected]

Overview

Entrada Therapeutics' mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada's technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Dipal Doshi

        

Chief Financial Officer

Kory Wentworth

        

Chief Medical Officer

Nerissa Kreher

        

Chief Operating Officer

Nathan Dowden

        

Chief Scientific Officer

Natarajan Sethuraman

        

VP - General Counsel

Jared Cohen

        

VP - Human Resources

Kerry Robert

        

Browse more venture capital transactions:

Prev: 12/19/2018: Winestyr venture capital transaction
Next: 12/20/2018: Cambridge Mobile Telematics venture capital transaction

Share this article

Where The Data Comes From

We do our best to document all VC transactions involving tech companies. VC investment data records on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary